{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=nivolumab&page=5", "query": { "intervention": "nivolumab", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 1206, "total_pages": 121, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=nivolumab&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=nivolumab&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T09:24:06.220Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03214250", "title": "Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "APX005M", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Parker Institute for Cancer Immunotherapy", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 129, "start_date": "2017-07-21", "completion_date": "2022-02-25", "has_results": true, "last_update_posted_date": "2022-12-23", "last_synced_at": "2026-10-22T09:24:06.220Z", "location_count": 7, "location_summary": "Los Angeles, California • San Francisco, California • Stanford, California + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03214250" }, { "nct_id": "NCT04900818", "title": "Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Advanced Cancer", "Metastatic Cancer", "Gastric Cancer", "Gastroesophageal Junction Carcinoma", "Esophageal Adenocarcinoma", "PDAC - Pancreatic Ductal Adenocarcinoma", "Biliary Tract Cancer (BTC)" ], "interventions": [ { "name": "TJ033721 (givastomig)", "type": "DRUG" }, { "name": "TJ033721 (givastomig) , nivolumab, chemotherapy", "type": "DRUG" }, { "name": "TJ033721 (givastomig), chemotherapy", "type": "DRUG" }, { "name": "TJ033721 (givastomig), durvalumab, chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "I-Mab Biopharma US Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 330, "start_date": "2021-06-29", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-10-22T09:24:06.220Z", "location_count": 11, "location_summary": "Orange, California • Aurora, Colorado • Layfayette, Indiana + 7 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Layfayette", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04900818" }, { "nct_id": "NCT04295863", "title": "Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Cancer" ], "interventions": [ { "name": "Nivolumab Standard", "type": "DRUG" }, { "name": "Pembrolizumab Standard", "type": "DRUG" }, { "name": "Nivolumab Extended", "type": "DRUG" }, { "name": "Pembrolizumab Extended", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 264, "start_date": "2020-06-25", "completion_date": "2026-04-12", "has_results": false, "last_update_posted_date": "2025-10-01", "last_synced_at": "2026-10-22T09:24:06.220Z", "location_count": 2, "location_summary": "Chicago, Illinois • Madison, Wisconsin", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04295863" }, { "nct_id": "NCT03824704", "title": "A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Carcinoma", "High Grade Serous Carcinoma", "Endometrioid Adenocarcinoma" ], "interventions": [ { "name": "Rucaparib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "pharmaand GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1, "start_date": "2019-08-23", "completion_date": "2020-08-24", "has_results": true, "last_update_posted_date": "2023-06-12", "last_synced_at": "2026-10-22T09:24:06.220Z", "location_count": 5, "location_summary": "Clovis, California • Savannah, Georgia • Covington, Louisiana + 2 more", "locations": [ { "city": "Clovis", "state": "California" }, { "city": "Savannah", "state": "Georgia" }, { "city": "Covington", "state": "Louisiana" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Burlington", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT03824704" }, { "nct_id": "NCT03572478", "title": "Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer", "Endometrial Cancer" ], "interventions": [ { "name": "Rucaparib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2018-08-14", "completion_date": "2020-10-01", "has_results": true, "last_update_posted_date": "2021-03-09", "last_synced_at": "2026-10-22T09:24:06.220Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03572478" }, { "nct_id": "NCT03325816", "title": "Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Cancer", "Small Cell Lung Cancer Extensive Stage" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "177Lu-DOTA0-Tyr3-Octreotate", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2017-11-20", "completion_date": "2020-08-11", "has_results": true, "last_update_posted_date": "2021-03-16", "last_synced_at": "2026-10-22T09:24:06.220Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Hackensack, New Jersey", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03325816" }, { "nct_id": "NCT03071406", "title": "Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Merkel Cell Carcinoma", "Skin Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Stereotactic Body Radiation Therapy (SBRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2017-03-14", "completion_date": "2026-09-19", "has_results": true, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-10-22T09:24:06.220Z", "location_count": 2, "location_summary": "Tampa, Florida • Columbus, Ohio", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03071406" }, { "nct_id": "NCT02864251", "title": "A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small-Cell Lung Carcinoma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 367, "start_date": "2017-03-17", "completion_date": "2022-10-17", "has_results": true, "last_update_posted_date": "2023-09-28", "last_synced_at": "2026-10-22T09:24:06.220Z", "location_count": 18, "location_summary": "Long Beach, California • Los Angeles, California • Orange, California + 12 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Redondo Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02864251" }, { "nct_id": "NCT03697564", "title": "Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer Stage IV" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]", "type": "DRUG" }, { "name": "Cabiralizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hitendra Patel", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2019-10-31", "completion_date": "2023-07-13", "has_results": true, "last_update_posted_date": "2025-08-06", "last_synced_at": "2026-10-22T09:24:06.220Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03697564" }, { "nct_id": "NCT02892734", "title": "Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2/Neu Negative", "Recurrent Inflammatory Breast Carcinoma", "Stage IV Breast Cancer", "Stage IV Inflammatory Breast Carcinoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 3, "start_date": "2017-09-18", "completion_date": "2019-02-04", "has_results": true, "last_update_posted_date": "2020-07-16", "last_synced_at": "2026-10-22T09:24:06.220Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02892734" } ] }